이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

VRC01 계열 항체의 추출을 위해 ATI를 받고 있는 HIV 감염자의 예방접종 연구

426c.Mod.Core-C4b 3M-052-AF + 명반 예방접종과 함께 VRC01 계열 항체의 유도를 위해 HIV에 걸린 사람들의 항레트로바이러스 분석 치료 중단(ATI)과 함께 보조제 추가

This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).

연구 개요

상세 설명

The aim of this study is to combine the ability of germline (GL)-targeting HIV-1 Envelope protein (Env)-derived immunogens to activate naïve B cells that express the unmutated GL forms of VRC01-class broadly neutralizing antibodies (bnAbs) with the booster capabilities of viral Envs that are expected to circulate in persons living with chronic HIV. The goals are: 1) to elicit VRC01-class GL and intermediate stage antibody responses in PLWH; 2) to identify the viral Envs that guided the maturation of the GL-VRC01 responses elicited by the GL-targeting Env immunogen; 3) during the time when viremia is detectable, the investigator will assess the stage of maturation of these VRC01 antibodies and if they affect viral replication; and 4) investigate how the virus may evolve to escape the activity of these antibodies.

연구 유형

중재적

등록 (실제)

35

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Alabama
      • Birmingham, Alabama, 미국, 35294-2170
        • Alabama CRS (Site # 31788)
    • Georgia
      • Atlanta, Georgia, 미국, 30303
        • The Ponce de Leon Center CRS (Site # 5802)
      • Decatur, Georgia, 미국, 30030
        • The Hope Clinic of the Emory Vaccine Center CRS (Site #31440)
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • BIDMC VCRS (Site # 32077)
    • New York
      • New York, New York, 미국, 10032
        • Columbia P&S CRS (Site # 30329)
    • Pennsylvania
      • Pittsburgh, Pennsylvania, 미국, 15213
        • University of Pittsburg CRS (Site # 1001)
    • Washington
      • Seattle, Washington, 미국, 98104
        • Seattle Vaccine and Prevention CRS (Site # 30331)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Able and willing to complete the informed consent process, including an Assessment of Understanding (AoU): Volunteer demonstrates an understanding of this study and completes a questionnaire prior to first vaccination with verbal demonstration of understanding of questionnaire items that were answered incorrectly.

  2. 18 to 55 years old, inclusive, on day of enrollment.

  3. Confirmed HIV infection as documented by medical records or confirmatory HIV testing at screening.

  4. On suppressive ART for at least 48 weeks prior to screening. ART is defined as a combination therapy regimen including at least 1 integrase inhibitor and 1 nucleoside reverse transcriptase inhibitor (such as Dovato™) or 2 nucleoside reverse transcriptase inhibitors plus integrase inhibitors. Changes in ARVs for reasons other than virologic failure (eg, tolerability, simplification, different formulation, drug-drug interaction profile) are allowed within 48 weeks prior to screening and up until 6 weeks prior to screening. A fully active alternative ARV regimen is available, in the opinion of the Investigator, in the event of discontinuation of the current ARV regimen with development of resistance.

  5. Plasma HIV RNA < 50 copies/mL (or lower limit of quantitation [LLOQ]) for at least 48 weeks prior to enrollment. NOTE: At least one viral load measurement within 48 weeks prior to the screening visit and another viral load from the screening prior to enrollment visit must be available for review. Two "blips" (ie, plasma HIV-1 RNA > LLOQ and < 400 copies/mL) are allowed if each blip is preceded and followed by values < LLOQ and if the blip(s) occur(s) more than 24 weeks prior to enrollment.

  6. CD4+ cell count > 450 cells/mm3 and CD4+ cell % ≥ 15% obtained within 40 days prior to enrollment.

  7. Available for clinic follow-up through the last clinic visit, willing to undergo leukapheresis, and willing to be contacted 12 months after the last study-product administration.

  8. Agrees not to enroll in another study of an investigational agent during participation in the trial. If a potential participant is already enrolled in another clinical trial, approvals from the other trial sponsor and the HVTN 807 PSRT are required prior to enrollment into HVTN 807.

  9. In good general health according to the clinical judgment of the site investigator.

  10. Physical examination and laboratory results without clinically significant findings that would interfere with assessment of safety or reactogenicity in the clinical judgement of the site investigator.

  11. Total serum calcium of ≥ 8.5 mg/dL.

  12. Hemoglobin (Hgb):

    • ≥ 10.0 g/dL for volunteers who were assigned female sex at birth (AFAB)
    • ≥ 11.0 g/dL for cisgender volunteers who were assigned male sex at birth (AMAB) and for transgender men who have been on hormone therapy for more than 6 consecutive months
    • ≥ 11.0 g/dL for transgender women who have been on hormone therapy for more than 6 consecutive months
    • For transgender volunteers who have been on hormone therapy for less than 6 consecutive months, determine Hgb eligibility based on their sex assigned at birth.
  13. Absolute neutrophil count (ANC) ≥ 750/mm3

    .

  14. Platelets ≥ 100,000/mm3

    .

  15. Alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) based on the institutional normal range and direct bilirubin within the institutional range of normal.

  16. Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2 as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation.

  17. For Group 1 volunteers: must agree to consistently use condoms from study week 14 through until viral load post-ATI is undetectable (at a minimum 20 weeks on study, at a maximum 64 weeks on study).

  18. For Group 1 volunteers

    • Persons of pregnancy potential

      • Must have a negative beta human chorionic gonadotropin (β-HCG) pregnancy test (urine or serum) on day of enrollment.
      • Must agree to use effective means of contraception from at least 21 days prior to enrollment until at least 8 weeks post last vaccination and viral load post-ATI is undetectable (at a minimum 20 weeks on study, at a maximum 64 weeks on study).
    • Volunteers who are AFAB or intersex at birth must agree to not seek pregnancy through alternative methods, such as oocyte retrieval, artificial insemination, or in vitro fertilization from at least 21 days prior to enrollment through until viral load post-ATI is undetectable (at a minimum 20 weeks on study, at a maximum 64 weeks on study).

  19. For Group 2 volunteers

    • Persons of pregnancy potential:

      • Must have a negative β-HCG pregnancy test (urine or serum) on day of enrollment.
      • Must agree to use effective means of contraception from at least 21 days prior to enrollment until 8 weeks after their last scheduled vaccination (study week 20).
    • Volunteers who are AFAB or intersex at birth must agree to not seek pregnancy through alternative methods, such as oocyte retrieval, artificial insemination, or in vitro fertilization from at least 21 days prior to enrollment through 8 weeks after their last scheduled vaccination timepoint.

Exclusion Criteria:

  1. Current receipt of ART other than nucleoside reverse transcriptase inhibitor and integrase inhibitor.

  2. Receipt of long-acting ART within 3 months of enrollment.

  3. Documented history of resistance to any components of the current ARV regimen.

  4. Known resistance to 1 or more drugs in 2 or more ARV drug classes. NOTE: M184V/I is an exception and should not be considered when assessing this criterion. Prior HIV resistance testing is not required.

  5. ART initiation during acute HIV-1 infection (defined as within 1 year of HIV-1 acquisition, if known).

  6. History of an HIV-associated malignancy (including Kaposi's sarcoma), and any type of lymphoma or virus-associated cancers.

  7. History of HIV-associated neurocognitive disease or progressive multifocal leukoencephalopathy.

  8. History of HIV-related illness under US Centers for Disease Control (CDC) Category C (except for recurrent pneumonia) within 10 years prior to screening, based on available medical history and assessed by the Investigator for clinical relevance. Anyone with a history of CD4 < 200 cells/mm3 on one or more occasions, based on available medical history and assessed by the Investigator for clinical relevance. Documentation of every case with history of CD4 < 200 cells/mm3 must be provided to the Sponsor and PSRT, who will determine eligibility on a case-by-case basis. NOTE: History of treated and resolved pulmonary tuberculosis (TB) will not be exclusionary.

  9. Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery within 36 months prior to enrollment or for whom such therapies are expected in the subsequent 12 months. NOTE: Minor surgical removal of localized skin cancers (squamous cell carcinoma, basal cell carcinoma) is not exclusionary.

  10. Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg), hepatitis C antibody without documented history of prior treatment and clearance, or hepatitis C virus RNA (HCV-RNA) in blood.

  11. Diagnosis of cirrhosis.

  12. Current untreated or incompletely treated active TB disease or untreated latent TB infection. NOTE: Individuals who are on treatment for latent TB with at least 4 weeks of treatment completed are not excluded.

  13. Volunteer who is breastfeeding or pregnant.

  14. Body mass index (BMI) ≥ 40. Enrollment of individuals with BMI ≥ 40, whom the site investigator assesses are in good health, may be considered by PSRT approval.

  15. Diabetes mellitus (DM). Type 2 DM controlled with diet alone (and confirmed by HgbA1c ≤ 8% within the last 6 months) or a history of isolated gestational diabetes are not exclusionary. Enrollment of individuals with Type 2 DM that is well controlled on hypoglycemic agent(s) may be considered by the PSRT on a case-by-case basis

  16. History of or current clinical atherosclerotic cardiovascular disease (ASCVD), as defined by 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines, including a previous diagnosis of any of the following:

    • Acute myocardial infarction
    • Acute coronary syndromes
    • Stable or unstable angina
    • Coronary or other arterial revascularization
    • Stroke
    • Transient ischemic attack
    • Peripheral arterial disease presumed to be of atherosclerotic origin
  17. Previous or current recipient of an investigational HIV vaccine (previous placebo/control recipients are not excluded).

  18. Receipt of non-HIV experimental vaccine(s) received within the last 1 year. Exceptions include vaccines that have subsequently undergone licensure or Emergency Use Authorization (EUA) by the FDA or World Health Organization (WHO) emergency use listing (EUL), or if outside the US, by the national Regulatory Authority (RA) authorizing this clinical trial.

  19. Congenital or acquired immunodeficiency, including systemic medication use likely to impair immune response to vaccine in the opinion of the site investigator, such as history of systemic corticosteroids (long-term use), immunosuppressive anti-cancer or other immunosuppressive agents, interleukins, systemic interferons, systemic chemotherapy, or other medications considered significant by the investigator within the 24 weeks prior. Note: HIV is not exclusionary.

  20. Blood products or immunoglobulin within 16 weeks prior to enrollment; receipt of immunoglobulin within 16 weeks prior to enrollment requires PSRT approval.

  21. Previous receipt of any anti-HIV monoclonal antibody.

  22. Receipt of any of the following vaccines within 4 weeks prior to enrollment:

    • Live replicating vaccines
    • Any mRNA-based vaccine with FDA licensure, FDA EUA, or WHO EUL
    • ACAM2000 vaccine > 30 days prior with a vaccination scab still present.
  23. Receipt of any vaccines that are not covered in #22 above within 14 days prior to enrollment. Please note this includes replication incompetent vaccines such as the Jynneos vaccine for the prevention of mpox (formerly known as monkeypox) disease.

  24. Initiation of antigen-based immunotherapy (AIT) for allergies within the previous year (stable immunotherapy is not exclusionary); inclusion of participants who initiated immunotherapy within the previous year requires PSRT approval. Note: Any AIT should be scheduled at least 14 days prior to enrollment.

  25. Receipt of investigational research agents with a half-life of 7 or fewer days within 4 weeks prior to enrollment. If a potential participant has received investigational agents with a half-life of greater than 7 days (or unknown half-life) within the past year, PSRT approval is required for enrollment.

  26. History of serious reaction (eg, hypersensitivity, anaphylaxis) to any vaccine or component of the study vaccine, including imidazoquinolone (eg, imiquimod).

  27. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema.

  28. Idiopathic urticaria within the past year.

  29. Bleeding disorder diagnosed by a clinician which would make study procedures a contraindication (eg, factor deficiency, coagulopathy, platelet disorder requiring special precautions).

  30. Seizure disorder; febrile seizures as a child or seizures secondary to alcohol withdrawal more than 5 years ago are not exclusionary.

  31. Asplenia or functional asplenia.

  32. Active duty and reserve US military personnel.

  33. Any other chronic or clinically significant condition that, in the clinical judgment of the investigator, would jeopardize the safety or rights of the study participant, including but not limited to: clinically significant forms of substance use or alcohol use disorder(s), serious psychiatric disorders, persons with any suicide attempt within the past 1 year (if between 1 and 2 years, consult PSRT for approval), or cancer that, in the clinical judgement of the site investigator, has potential for recurrence (excluding basal cell carcinoma).

  34. A participant with a history of a potential immune-mediated medical condition (PIMMC), either active or remote. Specific examples are listed in Appendix I (AESI Index). Not exclusionary: 1) Remote history of Bell's palsy (> 2 years ago) not associated with other neurologic symptoms and 2) mild psoriasis that does not require ongoing systemic treatment.

  35. Investigator concern for difficulty with venous access based on clinical history and physical examination. For example, persons with a history of intravenous drug use or substantial difficulty with previous blood draws.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Group 1 (ATI)

Group 1 will receive 2 doses of the vaccine at Week 0 and 12. Group 1 will transition to Schedule 2 at the Week 14 visit. The Schedule 2 "ATI with Monitoring" phase can last for 24 weeks OR until any antiretroviral therapy (ART) re-initiation criteria are met, OR the ATI can continue longer with the approval of the Protocol Safety Review Team (PSRT) and the participant's primary HIV healthcare provider. Group 1 will transition to Schedule 3, the "Follow-up on ART restart" phase that lasts until study week 64, regardless of the point where it begins.

100 mcg and 300 mcg

5 mcg

실험적: Group 2 (No ATI) Control

Group 2 transitions from Schedule 1 into Schedule 4, "Follow-up on ART," at the Week 14 visit, and remains on Schedule 4 through study week 64.

100 mcg and 300 mcg

5 mcg

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
참가자 수 국소 반응성 징후 및 증상
기간: 각 예방접종 후 14일
각 예방접종 후 14일
참가자 수 전신 반응원성 징후 및 증상
기간: 각 예방접종 후 14일
각 예방접종 후 14일
Number and description of serious adverse events (SAEs)
기간: 12 months following any receipt of study product

adverse events (AEs) will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult AEs

12 months following any receipt of study product
Number and description of medically attended adverse events (MAAEs)
기간: 12 months following any receipt of study product

adverse events (AEs) will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult AEs

12 months following any receipt of study product
Number and description of adverse events of special interest (AESIs)
기간: 12 months following any receipt of study product

adverse events (AEs) will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult AEs

12 months following any receipt of study product
Number and description of AEs leading to early participant withdrawal or permanent discontinuation and reason for withdrawal/discontinuation
기간: 12 months following any receipt of study product

adverse events (AEs) will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult AEs

12 months following any receipt of study product
Frequency of total Env-specific and CD4-bs-specific B cells, prior to ATI
기간: At baseline (week 0) and after each vaccination

as assessed by flow cytometry at baseline and after each vaccination

At baseline (week 0) and after each vaccination
Frequency of VRC01-class BCR sequences of isolated CD4-bs B cells, prior to ATI
기간: At baseline (week 0) and after each vaccination

, as assessed by B-cell sorting and BCR sequencing

At baseline (week 0) and after each vaccination
Frequency of Env-specific and CD4-bs-specific B cells
기간: After week 16

as assessed by flow cytometry

After week 16
Frequency of VRC01-class BCR sequences of isolated CD4-bs B cells
기간: After week 16

as assessed by B-cell sorting and BCR sequencing

After week 16

2차 결과 측정

결과 측정
기간
VRC01 항체 개발을 시작한 그룹 1 참가자와 그렇지 않은 참가자의 ATI 동안 Env 시퀀스를 비교합니다.
기간: 연구 기간 또는 연구 제품 수령 후 12개월
연구 기간 또는 연구 제품 수령 후 12개월
VRC01 클래스 전구체 및 중간 항체에 대한 VRC01 클래스 항체의 개발을 시작한 그룹 1 참가자로부터 선택된 RecEnv의 결합 정도
기간: 연구 기간 또는 연구 제품 수령 후 12개월
연구 기간 또는 연구 제품 수령 후 12개월
VRC01 클래스 BCR을 발현하는 B 세포에 대한 VRC01 클래스 항체의 개발을 시작한 그룹 1 참가자로부터 선택된 recEnv의 결합 정도.
기간: 연구 기간 또는 연구 제품 수령 후 12개월
연구 기간 또는 연구 제품 수령 후 12개월

기타 결과 측정

결과 측정
기간
연구 중에 분리된 VRC01 클래스 항체의 결합 및 중화 활성 정도
기간: 연구 기간 또는 연구 제품 수령 후 12개월
연구 기간 또는 연구 제품 수령 후 12개월
그룹 2 참가자(연구에서 바이러스가 나타나는 경우)와 그룹 1 참가자의 바이러스 서열 유사성 발생 빈도
기간: 연구 기간 또는 연구 제품 수령 후 12개월
연구 기간 또는 연구 제품 수령 후 12개월
ATI, 장기간의 바이러스혈증 및 시험 요구 사항(예: ART 스위치, 모든 성 활동에 대한 장벽 보호)에 대한 참가자 및 잠재적 참가자 동기, 인식 및 내성의 규모
기간: 연구 기간 또는 연구 제품 수령 후 12개월
연구 기간 또는 연구 제품 수령 후 12개월
ART를 중단하고 다시 바이러스에 감염되는 것에 대한 불안과 부주의한 파트너에게 HIV 전염에 대한 두려움을 포함하되 이에 국한되지 않는 사회적 혜택(예: 이타주의) 및 부정적인 사회적 영향의 정도
기간: 연구 기간 또는 연구 제품 수령 후 12개월
연구 기간 또는 연구 제품 수령 후 12개월
정보를 받았다는 인식, 의사 결정에 대한 명확성과 지원, 참여에 관한 선택에 대한 만족도를 포함하여 참가자 및 잠재적 참가자 의사 결정 품질의 정도.
기간: 연구 기간 또는 연구 제품 수령 후 12개월
연구 기간 또는 연구 제품 수령 후 12개월
각 백신 요법의 면역원성에 대한 반응률, 추가 바이러스학적 및 면역원성 분석은 다른 시점의 샘플을 포함하여 참가자의 하위 집합에서 수행될 수 있습니다.
기간: 연구 기간 또는 연구 제품 수령 후 12개월
연구 기간 또는 연구 제품 수령 후 12개월
HIV, 면역학, 백신, 임상시험 수행에 대한 이해 증진과 관련된 분석 수행
기간: 연구 기간 또는 연구 제품 수령 후 12개월
연구 기간 또는 연구 제품 수령 후 12개월

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 1월 3일

기본 완료 (실제)

2026년 10월 12일

연구 완료 (실제)

2026년 10월 12일

연구 등록 날짜

최초 제출

2023년 8월 17일

QC 기준을 충족하는 최초 제출

2023년 8월 17일

처음 게시됨 (실제)

2023년 8월 23일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • HVTN 807
  • 39013 (기타 식별자: DAIDS Document ID)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다